erlotinib hydrochloride has been researched along with tivozanib in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (tivozanib) | Trials (tivozanib) | Recent Studies (post-2010) (tivozanib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 105 | 23 | 100 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | tivozanib (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0709 | |
| Fibroblast growth factor 2 | Homo sapiens (human) | 0.0709 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.0709 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.0023 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.0032 | |
| Ephrin type-B receptor 2 | Homo sapiens (human) | 0.0175 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.0017 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0783 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.07 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
1 review(s) available for erlotinib hydrochloride and tivozanib
| Article | Year |
|---|---|
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |